In last trading session, Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) saw 0.35 million shares changing hands with its beta currently measuring 1.62. Company’s recent per share price level of $6.89 trading at -$0.54 or -7.27% at ring of the bell on the day assigns it a market valuation of $475.82M. That closing price of BCYC’s stock is at a discount of -316.11% from its 52-week high price of $28.67 and is indicating a discount of -7.55% from its 52-week low price of $7.41. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.41 million shares which gives us an average trading volume of 314.77K if we extend that period to 3-months.
For Bicycle Therapeutics Plc ADR (BCYC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.47. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) trade information
Upright in the red during last session for losing -7.27%, in the last five days BCYC remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $6.89 price level, adding 22.58% to its value on the day. Bicycle Therapeutics Plc ADR’s shares saw a change of -50.79% in year-to-date performance and have moved -23.19% in past 5-day. Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) showed a performance of -35.31% in past 30-days. Number of shares sold short was 4.4 million shares which calculate 16.09 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 28 to the stock, which implies a rise of 75.39% to its current value. Analysts have been projecting 26 as a low price target for the stock while placing it at a high target of 48. It follows that stock’s current price would drop -277.36% in reaching the projected high whereas dropping to the targeted low would mean a loss of -277.36% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -0.87% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -19.49% while estimates for its earnings growth in next 5 years are of -9.01%.
Bicycle Therapeutics Plc ADR (NASDAQ:BCYC)’s Major holders
Insiders are in possession of 1.75% of company’s total shares while institution are holding 92.06 percent of that, with stock having share float percentage of 93.69%. Investors also watch the number of corporate investors in a company very closely, which is 92.06% institutions for Bicycle Therapeutics Plc ADR that are currently holding shares of the company. BAKER BROS. ADVISORS LP is the top institutional holder at BCYC for having 9.4 million shares of worth $190.26 million. And as of 2024-06-30, it was holding 18.0796 of the company’s outstanding shares.
The second largest institutional holder is DEEP TRACK CAPITAL, LP, which was holding about 3.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.7135 of outstanding shares, having a total worth of $70.65 million.
On the other hand, T. Rowe Price Health Sciences Fund, Inc. and HARBOR FUNDS-Harbor Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.2 shares of worth $8.26 million or 2.51% of the total outstanding shares. The later fund manager was in possession of 1.0 shares on Jan 31, 2025 , making its stake of worth around $6.9 million in the company or a holder of 2.10% of company’s stock.
